2. Search Result
Search Result
Results for "

TEAD inhibitor

" in MedChemExpress (MCE) Product Catalog:

49

Inhibitors & Agonists

5

Peptides

1

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-155309
    LM-41

    		YAP Cancer
    LM-41 is a Flufenamic acid-derived TEAD inhibitor hat strongly reduce the expression of CTGF, Cyr61, Axl and NF2. LM-41 inhibits migration of human MDA-MB-231 breast cancer cells .
    LM-41
  • HY-147088
    TEAD-IN-2

    		YAP Cancer
    TEAD-IN-2 is a novel, orally active inhibitor of transcriptional enhancer associate domain (TEAD) and modulates TEAD by ubiquitination and/or degradation by compounds. TEAD-IN-2 can be used for the research of a variety of diseases, disorders or conditions associated with TEAD .
    TEAD-IN-2
  • HY-147135
    MYF-03-69

    TEAD-IN-3

    		 YAP Cancer
    MYF-03-69 (TEAD-IN-3) is a potent and irreversible TEAD inhibitor. MYF-03-69 disrupts YAP-TEAD association, suppresses TEAD transcriptional activity and inhibits cell growth of Hippo signaling defective malignant pleural mesothelioma (MPM) .
    MYF-03-69
  • HY-153811
    IAG933

    YAP-TEAD-IN-3

    		 YAP Apoptosis Cancer
    IAG933 (YAP-TEAD-IN-3) is an orally available YAP/TAZ-TEAD inhibitor that has anti-tumor effects and promotes apoptosis. IAG933 YAP-TEAD-IN-3 inhibits Avi-human TEAD 4217-434, with an IC50 value of 9 nM .
    IAG933
  • HY-163173
    TEAD-IN-8

    		YAP Cancer
    TEAD-IN-8 is a novel TEAD inhibitor, which potently and specifically inhibits TEAD-YAP transcriptional activities. TM2, alone or in combination with MEK inhibitors, exhibits potent antiproliferative effects in YAP-dependent cancer cells .
    TEAD-IN-8
  • HY-161569
    TEAD-IN-11

    		YAP Cancer
    TEAD-IN-11 (compound 38) has a good inhibitory effect on TEAD1 (IC50=8.7 nM), TEAD2 (IC50=3.4 nM), TEAD3 (IC50=5.6 nnM). TEAD-IN-11 has good selective activity against TEAD1-3 as a covalent inhibitor. TEAD-IN-11 can be used for cancer research .
    TEAD-IN-11
  • HY-161568
    TEAD-IN-10

    		YAP Cancer
    TEAD-IN-10 (compound 15) has good selective activity and inhibitory effect on TEAD1 (IC50=14 nM), TEAD2 (IC50=179 nM) and TEAD3 (IC50=4 nnM) as a covalent inhibitor. TEAD-IN-10 can be used for cancer research .
    TEAD-IN-10
  • HY-155310
    AF-2112

    		YAP Cancer
    AF-2112 is a Flufenamic acid-derived TEAD inhibitor hat strongly reduce the expression of CTGF, Cyr61, Axl and NF2.
    AF-2112
  • HY-161443
    TEAD-IN-9

    		YAP Cancer
    TEAD-IN-9 (compound 17) is a TEAD1 inhibitor with an IC50 of 0.29 μM. TEAD-IN-9 targets the palmitoyl pocket of TEAD, thereby effectively inhibiting the binding of YAP-TEAD and blocking the transcriptional function of YAP-TEAD .
    TEAD-IN-9
  • HY-163732
    TEAD-IN-16

    		YAP Cancer
    TEAD-IN-16 (compound BC-011) is a potent inhibitor of TEAD, with the IC50 of 72.43 μM. TEAD-IN-16 plays an important role in cancer research .
    TEAD-IN-16
  • HY-134955
    VT103
    2 Publications Verification

    		 YAP Cancer
    VT103, an analog of VT101, is an orally active and selective TEAD1 protein palmitoylation inhibitor. VT103 inhibits YAP/TAZ-TEAD promoted gene transcription, blocks TEAD auto-palmitoylation, and disrupts interaction between YAP/TAZ and TEAD. VT103 can be used for the research of cancer .
    VT103
  • HY-147208
    MSC-4106

    		YAP Cancer
    MSC-4106 is an orally active and potent inhibitor of YAP/TAZ-TEAD. MSC-4106 inhibits TEAD1 or TEAD3 auto-palmitoylation and shows inhibitory effect on NCI-H226 tumor xenograft model .
    MSC-4106
  • HY-P2244
    YAP-TEAD-IN-1
    2 Publications Verification

    		 YAP Cancer
    YAP-TEAD-IN-1 is a potent and competitive inhibitor of?YAP–TEAD interaction (IC50=25 nM). YAP-TEAD-IN-1 is a 17mer peptide and shows a higher the binding affinity to TEAD1 (Kd=15 nM) than YAP (50-171) (Kd=40 nM) .
    YAP-TEAD-IN-1
  • HY-P2244A
    YAP-TEAD-IN-1 TFA
    2 Publications Verification

    		 YAP Cancer
    YAP-TEAD-IN-1 TFA is a potent and competitive peptide inhibitor of?YAP-TEAD interaction (IC50=25 nM). YAP-TEAD-IN-1 TFA is a 17mer peptide and shows a higher the binding affinity to TEAD1 (Kd=15 nM) than YAP (50-171) (Kd= 40 nM) .
    YAP-TEAD-IN-1 TFA
  • HY-158395
    TEAD-IN-13

    		YAP Cancer
    TEAD-IN-13 (64) is an orally active TEAD inhibitor, with an IC50 of <100 nM and a half-life of 3.2 h in mouse .
    TEAD-IN-13
  • HY-158396
    TEAD-IN-14

    		YAP Cancer
    TEAD-IN-14 (75a) is an orally active TEAD inhibitor, with an IC50 of <100 nM and a half-life of 2.3 h in mouse .
    TEAD-IN-14
  • HY-169316
    YAP/TAZ inhibitor-4

    		YAP Cancer
    YAP/TAZ inhibitor-4 (Compound 45) is an inhibitor of YAP/TAZ, exhibiting TEAD transcriptional activation inhibitory activity by suppressing the binding of YAP or TAZ to TEAD .
    YAP/TAZ inhibitor-4
  • HY-125269
    TED-347
    5+ Cited Publications

    		 YAP Cancer
    TED-347 is a potent, irreversible, covalent and allosteric inhibitor at YAP-TEAD protein-protein interaction with an EC50 of 5.9 μM for TEAD4⋅Yap1 protein-protein interaction. TED-347 specifically and covalently bonds with Cys-367 within the central pocket of TEAD4 with a Ki of 10.3 μM. TED-347 blocks TEAD transcriptional activity and has antitumor activity .
    TED-347
  • HY-151525
    YAP-TEAD-IN-2

    		YAP Cancer
    YAP-TEAD-IN-2 (compound 6) is a potent YAP-TEAD PPI (protein-protein interaction) inhibitor with IC50 is 2.7 nM .
    YAP-TEAD-IN-2
  • HY-158394
    TEAD-IN-12

    		YAP Cancer
    TEAD-IN-12 (58B) is an orally active TEAD inhibitor, with an IC50 of <100 nM and a half-life of 3.6 h in mouse .
    TEAD-IN-12
  • HY-155338
    SWTX-143

    		YAP Cancer
    SWTX-143 is an orally active YAP/TAZ-TEAD inhibitor that binds to the palmitoylation pocket of all four TEAD isoforms. SWTX-143 causes irreversible and specific inhibition of the transcriptional activity of YAP/TAZ-TEAD and shows antitumor activity .
    SWTX-143
  • HY-139603
    MYF-01-37

    		YAP Cancer
    MYF-01-37 is a covalent TEAD inhibitor targeting Cys380. MYF-01-37 has a reversible inhibition on YAP/TEAD interaction .
    MYF-01-37
  • HY-168505
    MSC-5046

    		YAP Cancer
    MSC-5046 is a selective TEAD1 inhibitor .
    MSC-5046
  • HY-B1221
    Flufenamic acid
    5+ Cited Publications

    		 COX AMPK Potassium Channel Chloride Channel Calcium Channel Parasite Inflammation/Immunology
    Flufenamic acid is a non-steroidal anti-inflammatory agent, inhibits cyclooxygenase (COX), activates AMPK, and also modulates ion channels, blocking chloride channels and L-type Ca 2+ channels, modulating non-selective cation channels (NSC), activating K + channels. Flufenamic acid binds to the central pocket of TEAD2 YBD and inhibits both TEAD function and TEAD-YAP-dependent processes, such as cell migration and proliferation.
    Flufenamic acid
  • HY-134956
    VT104

    		YAP Cancer
    VT104 is a potent and orally active YAP/TAZ inhibitor. VT104 prevents palmitoylation of endogenous TEAD1 and TEAD3 proteins. VT104 can be used in research of cancer .
    VT104
  • HY-158342
    PROTAC TEAD degrader-1

    		PROTACs YAP Cancer
    PROTAC TEAD degrader-1 (Compound 27) is a PROTAC degrader for transcriptional enhanced associate domain (TEAD). PROTAC TEAD degrader-1 selectively degrades the Flag TEAD2 in a ubiquitin proteasome-dependent manner, with a DC50 of 54.1 nM in 293T cells, inhibits proliferation of NF2-deficient NCI-H226 with an IC50 of 0.21 μM, and regulates expressions of yes associated protein (YAP) target genes. (Pink: TEAD ligand (HY-158400); Black: linker (HY-W008474); Blue: E3 ligase ligand (HY-W087383))
    PROTAC TEAD degrader-1
  • HY-147214
    GNE-7883

    		YAP Cancer
    GNE-7883 is a pan-TEAD inhibitor that blocks the association of YAP/TAZ with TEAD. GNE-7883 effectively reduces chromatin accessibility at TEAD motifs, inhibits cell proliferation in multiple cell line models, and achieves strong anti-tumor efficacy in vivo. In addition, GNE-7883 effectively overcomes intrinsic and acquired resistance to KRAS (Kirsten rat sarcoma viral oncogene homolog) G12C inhibitors in multiple preclinical models by inhibiting YAP/TAZ activation .
    GNE-7883
  • HY-138565
    K-975
    10+ Cited Publications

    		 YAP Cancer
    K-975 is a potent, selective and orally active TEAD inhibitor, with a strong inhibitory effect against protein-protein interactions between YAP1/TAZ and TEAD. K-975 covalently binds to Cys359 located in the palmitate-binding pocket of TEAD via an acrylamide structure. K-975 exhibits antitumor activity on malignant pleural mesothelioma .
    K-975
  • HY-126621
    DC-TEADin02

    		YAP Cancer
    DC-TEADin02 is a potent TEAD autopalmitoylation inhibitor. DC-TEADin02 has TEAD autopalmitoylation inhibitory with the IC50 value of 197 nM. DC-TEADin02 can be used for the research of development, regeneration and tissue homeostasis .
    DC-TEADin02
  • HY-139330
    MGH-CP1

    		Apoptosis Cancer
    MGH-CP1 is a potent and orally active TEAD2 and TEAD4 auto-palmitoylation inhibitor with IC50s of 710 nM and 672 nM, respectively. MGH-CP1 can decrease the palmitoylation levels of endogenous or ectopically expressed TEAD proteins in cells. MGH-CP1 can suppress Myc expression, inhibit epithelial over-proliferation, and induce apoptosis when together with Lats1/2 deletion .
    MGH-CP1
  • HY-B1221S
    Flufenamic acid-d4

    		Isotope-Labeled Compounds COX AMPK Potassium Channel Chloride Channel Calcium Channel Parasite Inflammation/Immunology
    Flufenamic acid-d4 is deuterium labeled Flufenamic acid. Flufenamic acid is a non-steroidal anti-inflammatory agent, inhibits cyclooxygenase (COX), activates AMPK, and also modulates ion channels, blocking chloride channels and L-type Ca 2+ channels, modulating non-selective cation channels (NSC), activating K+ channels. Flufenamic acid binds to the central pocket of TEAD2 YBD and inhibits both TEAD function and TEAD-YAP-dependent processes, such as cell migration and proliferation.
    Flufenamic acid-d4
  • HY-B1221S1
    Flufenamic acid-13C6

    		Isotope-Labeled Compounds COX AMPK Potassium Channel Chloride Channel Calcium Channel Parasite Inflammation/Immunology
    Flufenamic acid- 13C6 is the 13C6 labeled Flufenamic acid. Flufenamic acid is a non-steroidal anti-inflammatory agent, inhibits cyclooxygenase (COX), activates AMPK, and also modulates ion channels, blocking chloride channels and L-type Ca 2+ channels, modulating non-selective cation channels (NSC), activating K+ channels. Flufenamic acid binds to the central pocket of TEAD2 YBD and inhibits both TEAD function and TEAD-YAP-dependent processes, such as cell migration and proliferation.
    Flufenamic acid-13C6
  • HY-B1221R
    Flufenamic acid (Standard)

    		COX AMPK Potassium Channel Chloride Channel Calcium Channel Parasite Inflammation/Immunology
    Flufenamic acid (Standard) is the analytical standard of Flufenamic acid. This product is intended for research and analytical applications. Flufenamic acid is a non-steroidal anti-inflammatory agent, inhibits cyclooxygenase (COX), activates AMPK, and also modulates ion channels, blocking chloride channels and L-type Ca 2+ channels, modulating non-selective cation channels (NSC), activating K + channels. Flufenamic acid binds to the central pocket of TEAD2 YBD and inhibits both TEAD function and TEAD-YAP-dependent processes, such as cell migration and proliferation.
    Flufenamic acid (Standard)
  • HY-B0990
    Thiostrepton
    15+ Cited Publications

    		 Bacterial Antibiotic Infection
    Thiostrepton is a thiazole antibiotic which selectively inhibits FOXM1. FOXM1 binds to YAP/TEAD complex. YAP/TEAD/FOXM1 complex binding at regulatory regions of genes governing cell cycle may impact cell proliferation .
    Thiostrepton
  • HY-162012
    HC-258

    		YAP Cancer
    HC-258 (compound 26) binds with the cysteine in TEAD’s PA pocket. HC-258 reduces the CTGF, CYR61, AXL, and NF2 transcript levels and inhibits the migration of MDA-MB-231 breast cancer cells .
    HC-258
  • HY-163644
    VT-105

    		Others Cancer
    VT-105 is a potent and selective TEAD autopalmitoylation inhibitor that inhibits proliferation and tumor growth in NF2-deficient mesothelioma.
    VT-105
  • HY-168506
    MSC-1254

    		YAP Cancer
    MSC-1254 is a reversible, selective and covalent TEAD1 inhibitor. MSC-1254 can be used for the study of cancer .
    MSC-1254
  • HY-153585
    IK-930
    1 Publications Verification

    		 YAP Cancer
    IK-930 (compound I-32) is a potent and orally active TEAD inhibitor with an EC50 value of <0.1 µM .
    IK-930
  • HY-168085
    CV-4-26

    		YAP Apoptosis Cancer
    CV-4-26 (Compound 22) is a covalent inhibitor of TEAD. CV-4-26 inhibits YAP/TEAD-based transcription, leading to the reduction of CTGF and CYR61 expression. CV-4-26 inhibits Huh7 and HepG2 cell colony formation, induces cell cycle arrest, and apoptosis. CV-4-26 shows antitumor activity against hepatocellular carcinoma (HCC) and hepatoblastoma (HB) .
    CV-4-26
  • HY-160657
    DC-TEADin04

    		Others Others
    DC-TEADin04 has weak inhibitory activity against TEAD4 palmitoylation .
    DC-TEADin04
  • HY-150256
    YTP-17

    		YAP Cancer
    YTP-17 is an orally active YAP-TEAD protein-protein interaction inhibitor with an IC50 of 4 nM. YTP-17 shows anti-tumor efficacy .
    YTP-17
  • HY-134957
    VT107
    3 Publications Verification

    		 YAP Cancer
    VT-107, as an analogous to VT104, is an orally active and potent pan-TEAD auto-palmitoylation inhibitor. VT-107 can be used for the research of cancer .
    VT107
  • HY-147322
    YAP/TAZ inhibitor-2

    		YAP Cancer
    YAP/TAZ inhibitor-2 is a potent and orally active TEAD-YAP/TAZ inhibitor with an EC50 value of 3 nM. YAP/TAZ inhibitor-2 shows anti-proliferative activity. YAP/TAZ inhibitor-2 shows antitumor activity .
    YAP/TAZ inhibitor-2
  • HY-157083
    mCMY020

    		YAP Cancer
    mCMY020 is a covalent inhibitor of TEAD. mCMY020 effectively reduces YAP (Yes-associated protein)-driven transcription and selectively slows the proliferation of Hippo-deficient cancer cells. mCMY020 can be used in cancer research .
    mCMY020
  • HY-134956B
    (R)-VT104

    		YAP Cancer
    (R)-VT104 is the R-enantiomer of VT104. (R)-VT104 shows an IC50 value of 0.1-1 μΜ for firefly luciferase. VT104 is an orally active and pan-TEAD auto-palmitoylation inhibitor .
    (R)-VT104
  • HY-P1728
    Super-TDU (1-31)

    		YAP Cancer
    Super-TDU (1-31) is a peptide fragment of Super-TDU. Super-TDU (1-31) is an inhibitor of YAP-TEAD complex. Super-TDU shows potent anti-tumor activity and suppresses tumor growth in gastric cancer mouse model .
    Super-TDU (1-31)
  • HY-B0146
    Verteporfin
    Maximum Cited Publications
    172 Publications Verification

    CL 318952

    		 YAP Apoptosis Autophagy Cancer
    Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis . Verteporfinis an autophagy inhibitor that blocks autophagy at an early stage by inhibiting autophagosome formation .
    Verteporfin
  • HY-P1728A
    Super-TDU (1-31) (TFA)

    		YAP Cancer
    Super-TDU (1-31) TFA is a peptide fragment of Super-TDU. Super-TDU (1-31) TFA is an inhibitor of YAP-TEAD complex. Super-TDU TFA shows potent anti-tumor activity and suppresses tumor growth in gastric cancer mouse model .
    Super-TDU (1-31) (TFA)
  • HY-B0146R
    Verteporfin (Standard)

    CL 318952 (Standard)

    		 YAP Apoptosis Autophagy Cancer
    Verteporfin (Standard) is the analytical standard of Verteporfin. This product is intended for research and analytical applications. Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis . Verteporfinis an autophagy inhibitor that blocks autophagy at an early stage by inhibiting autophagosome formation .
    Verteporfin (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: